BioLargo, Inc. · OTC:BLGO

BioLargo — LD Micro October 2025

30 slides from BioLargo's conference presentation, Oct 20, 2025

  1. Slide 1: We Make Life Better

    We Make Life Better BioLargo An innovation engine for a better tomorrow LD Micro October 2025 Stock Symbol: OTCQX:BLGO

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement

  3. Slide 3: Who we are

    Who we are > Innovators, > Passionate about > Driven by a mission scientists, engineers, sustainability and to make life better and entrepreneurs human health

  4. Slide 4: What we do

    What we do > Best-in-class > Focus on problems > Aim for solutions for without good partnerships and cleantech problems solutions spin-outs to capitalize on our IP

  5. Slide 5: The BioLargo Innovation Engine

    The BioLargo Innovation Engine (QBiglaroo BioLargo We Make Life Better GPBiok 2g — corn 6 BioLargo — R&D Investing in... ENERGY TECHNOLOGIES @ cura #.BioLargo (Bilao 5

  6. Slide 6: The BioLargo Portfolio Addresses AI Infrastructure Chokepoints

    The BioLargo Portfolio Addresses Al Infrastructure Chokepoints (Eee BioLer go * Cellinity batteries We Make Life Better * Supply chain independence + Water reuse - Up to 90% water reduction + PFAS & contaminant management BioLargo Al Solutions * Recycling (eet |e)

  7. Slide 7: The Unseen Value of the BioLargo Portfolio

    The Unseen Value of the BioLargo Portfolio ENERGY + Unmatched technologies + Capital-conserving strategy + Highly qualified people * Driven for high impact $750M+ These are targeted minimum future values for our portfolio companies, based on management's modeling. This analysis does not include othe

  8. Slide 8: BioLargo Value: The sum of the parts bull case debate

    BioLargo Value: “The sum of the parts bull case debate” Battery $44 Million $2.5 Billion+ 95% @ Medical $95 Million $1 Billion+ 49% 7) PFAS $60 Million* $750 Milion+ 400% a Odor $40 Million* $100 Million 100% iy] Engineering NA NA 70/30% profit split 6 BioLargo 200 Million* | $4.35 Billion* 50- 87X

  9. Slide 9: Energy Technologies: Cellinity Liquid Sodium Battery

    ‘TECHNOLOGIES CELLINITY Liquid Sodium Battery (Biola 9

  10. Slide 10: Engineering Bona Fides

    Engineering Bona Fides * Engineers and scientists with decades of experience in cleantech development and services + Expertise in energy, regulatory affairs, process design, and battery chemistry * Industry veterans from CB&l and Shaw Engineering G8itewe |e

  11. Slide 11: Clean energy's next trillion-dollar business

    Ea -- rs eet Clean energy’s next trillion-dollar business ee mee ae aig et “global energy storage experts have predicted the global supply of battery energy storage will need to increase from today's 200 gigawatts to more than a terawatt by 2030 and more than five terawatts by 2050, fueling a market

  12. Slide 12: The Problems with Lithium Batteries

    The Problems with Lithium Batteries > Explosive > High risk of thermal runaway > Global supply chain risk > Poor environmental outcomes

  13. Slide 13: Cellinity battery technology

    BioLargo's Cellinty battery technology was created to provide a better option for battery thium-ion, empowering grid stability and storage of renewable energy. CELLINITY BATTERY 5 Cellinity is: 2 SUSTAINABLE 7 (A 2 7 1 Le: eee ot e bee ©: |OO} C=LLINITY [O: 4 EFFICIENT Ismoreeneray dense, making it

  14. Slide 14: Compared to other Battery Chemistries

    Compared to other Battery Chemistries Peay Molten Biolargo Specification Sodium-ion calcium Lead acid Battery Ceobsivonce) antimony (Uiquid Sodium) Energy density (Wtvkg) 150-190 75-165 tow 30-50 45-60 382 Life cycle (down to 80%. No loss in ? No lossin eae 500-1000 2,000-6,000 Pretiecks 200-300 110

  15. Slide 15: Products

    Products Gpitewe a

  16. Slide 16: We need better batteries

    We need better batteries Data Center & Al Infrastructure Boom Resilience Balancing Arbitrage — buy low & sell high Enabling Renewable Energy- Intermittency

  17. Slide 17: Independent Evaluation Confirms Breakthrough Performance of Cellinity Battery

    a EN=RGY TECHNOLOGIES Independent Evaluation Confirms Breakthrough Performance of BioLargo’s Cellinity Battery Technology for Grid-Scale Energy Storage 6/25

  18. Slide 18: Commercialization Pathway and Valuation Roadmap

    BioLargo Commercialization Pathway and ENERGY Valuation Roadmap ea $ lion Nes valuation ANY A $155 billion NPV FR Completed third-party Comglete plot . validation ul Cetin >$25billion mendes Seep cas ars ie fecores or future city etary pac sting pavers aniston Build component Make and test secure pr

  19. Slide 19: Globally Scalable: sell factories, not batteries

    Globally Scalable Business model: sell factories, not batteries Factories that are owned and operated locally, with BioLargo holding a minority position Adapt capacity to meet demand scale: giga- vs micro-factory Why own a Cellinity factory? * Best available battery for a hungry market * Capitalize

  20. Slide 20: Revenue Streams

    Revenue Streams Royalty Income ‘+ 6% royalty on gross sales ‘+ ~$30 million per factory once at capacity REPRESENTATIVE BATTERY FACTORY PARTNERSHIP PROJECT Development @aappne _}_@paigtagt $50 milion revenue to BETI on average project, (engineering, equipment, training, etc) nstruction of Factory Pr

  21. Slide 21: Giga Factory Model - Summary

    Giga Factory Model - Summary ‘be of Unis Prasuces as "750 ‘730| "750 "73 ees ee ee ee (Cont of Goss Sls) | aeons * era * ierenom|’ Teams * isa] | [GROGS REVENUE 4 ona7s 4 175743706 todas |= azznsas | Te2I9ATo ‘Opting Expenses (SEA) 7 1 Pore & oureens $s wero $ asoKon s 3 zon] Comet Lab tice Pay) $ "

  22. Slide 22: BETI Roll-Up Model: Factory Development & Operation

    BETI Roll-Up Model: Factory Development & Operation Tas 11 BioLargo cet Income & peeve = EN=RGY BETI Equity Capital Distribution 19% per year TECHNOLOGIES SS aT heoesworna Se te — nt a 1 so. nee! “cel seel steel sous) des |owring apnea (588) a + i yet totes Oe Cy + wseools tums raro|s tases tamraw|s

  23. Slide 23: MOUs for Factory Projects with partners

    MOUs for Factory Projects with partners + innovative financing strategies to create big wins for the communities and BioLargo* + Arizona * Texas * Latin America + New Jersey + Norway + Africa * Puerto Rico * Tribal Lands

  24. Slide 24: Clyra Medical Technologies

    Clyra Medical Technologies Entering the Next Stage of Commercialization + FDA Cleared * Major distribution agreements already signed and preparing to launch sales + Expanded Market Access — + US. & international markets * 6,100 hospitals, 6,300 surgery centers, and 2,200 wound care clinics in the U.

  25. Slide 25: PFAS Treatment and Other Water Treatment Technologies

    PFAS Treatment and Other Water Treatment Technologies * (New Jersey) — AEC unit delivered * US and State EPA — cooperation / validation + Performance Breakthroughs: = Removed PFAS <4 ppt (exceeds new EPA advisory) = Removed ultrashort PFAS — rare industry capability * Large Industry Pilots — wastewa

  26. Slide 26: BioLargo Protects Its Intellectual Property

    ONM BioLargo Protects Its Intellectual i Property That Built a National Brand - Environmental and Pooph's License Was Revoked for Private Label Non-Payment and Unauthorized Activities Products enn CA mh a “orang fanart ice iene Ser hes aoa Soe a ae pacar creat Snel oapeno yee uments ooh nutes taoe o

  27. Slide 27: Engineering & Environmental Services

    Engineering & environmental engineering services. Oa relationships. Environmental Services + Revenue up — strong demand for + Strategic Value * Provides stable cash flow & deepens client Expanding Our Reach * Strengthens core technology commercialization * Innovation specialists GBitewe ar

  28. Slide 28: Net Stockholders' Equity

    MILLIONS 87 $6 6 4 8 82 $1 s so) $2) $0) NET STOCKHOLDER'S EQUITY END OF Q2 2018 2019 Trends are not necessarily indicative of future performance ‘Note that $3.8 milion in nates fram Pooph in default and subject to impairment review and Clyra increased investment capital inflow in review 2024 (Biota

  29. Slide 29: Annual Run Rate and Q2 2025 Financials

    MILLIONS $20 $8 $6 a7) $2 $0 $8 $6 $4 $2 $0 ANNUAL RUN RATE ‘highly dependent on our partners" performance. . The Pooph Effect! zoe 2019 -—«2020««2021 «2022 «2023-2024 2025 RUN RATE AS OF ae ‘Trends ore not necessarily indicative of future performance, ond fture revenues ore Q2 2025 Finan: Revenue *

  30. Slide 30: The BioLargo Family of Companies

    The BioLargo Family of Companies 6 Bio! ioLargo BioLargo nc. is a sustainable science, technology & full-service enviromental engineering company that makeslife better by delivering world-class products and services across abroad range of industries, witha drive to deliver clean water, clean air, an

BioLargo — LD Micro October 2025 on 6ix